SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.

Highlights Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

688321

CNE100003LW0

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 20/05/2024 am IST			5-day change	1st Jan Change
22.49 ^CNY	+0.40%		-4.09%	+2.46%

30/04	National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma	CI
28/04	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma	30/04	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28/04	CI
Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03/04	CI
Shenzhen Chipscreen Biosciences Co., Ltd. commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024.	27/03	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis	18/03	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Chipscreen Biosciences' New Production Line Passes Regulatory Inspection	23/11	MT
Chipscreen Biosciences Gets Regulatory Nod for China Clinical Trial of Psoriasis Drug	01/11	MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	11/23/11	CI
Chinese Drug Regulator to Prioritize Shenzhen Chipscreen Biosciences' Application for Chidamide Tablets	21/23/21	MT
Shenzhen Chipscreen Biosciences Gets Nod for Tumor Drug Trial	27/23/27	MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	30/22/30	CI
Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback announced on July 7, 2021, has expired.	19/22/19	CI
Akeso, Chipscreen Bio to Jointly Carry Out Clinical Trials of Combination Therapy for Lung Cancer	02/22/02	MT
Akeso, Inc. Announces Collaboration with Chipscreen Biosciences to Initiated A Clinical Trial of Pd-1/Ctla-4 Bi-Specific Antibody in Combination with Chiauranib for Pd-(L)1 Pretreated Es-Sclc	02/22/02	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

688321

CNE100003LW0

Highlights

Filters